Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

[Pharmacoeconomic impact of compliance].

Agh T, Mészáros A.

Acta Pharm Hung. 2010;80(2):75-80. Hungarian.

PMID:
20684381
2.

Overview of pharmacoeconomics and pharmaceutical outcomes evaluations.

Reeder CE.

Am J Health Syst Pharm. 1995 Oct 1;52(19 Suppl 4):S5-8. Review.

PMID:
8846244
3.

The practical impact of pharmacoeconomics on institutional managers.

Cooke J.

Pharmacoeconomics. 1994 Oct;6(4):289-97.

PMID:
10147466
4.

The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature.

Hughes DA, Bagust A, Haycox A, Walley T.

Health Econ. 2001 Oct;10(7):601-15. Review.

PMID:
11747044
5.

Pharmacoeconomic impact of non-compliance with statins.

Peterson AM, McGhan WF.

Pharmacoeconomics. 2005;23(1):13-25. Review.

PMID:
15693725
6.

The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.

Hiligsmann M, Boonen A, Rabenda V, Reginster JY.

Expert Rev Pharmacoecon Outcomes Res. 2012 Apr;12(2):159-66. doi: 10.1586/erp.12.8. Review.

PMID:
22458617
7.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
8.

Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.

Thwaites R, Townsend RJ.

Pharmacoeconomics. 1998 Feb;13(2):175-80.

PMID:
10178645
9.

A pharmacoeconomic analysis of compliance gains on antipsychotic medications.

Damen J, Thuresson PO, Heeg B, Lothgren M.

Appl Health Econ Health Policy. 2008;6(4):189-97. doi: 10.2165/00148365-200806040-00002.

PMID:
19382819
10.

A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.

Glazer WM, Ereshefsky L.

J Clin Psychiatry. 1996 Aug;57(8):337-45.

PMID:
8752015
11.

Pharmacoeconomic aspects of poor adherence: can better adherence reduce healthcare costs?

Golay A.

J Med Econ. 2011;14(5):594-608. doi: 10.3111/13696998.2011.597808. Epub 2011 Jul 7. Review.

PMID:
21732903
12.

A review of the literature on the economics of noncompliance. Room for methodological improvement.

Cleemput I, Kesteloot K, DeGeest S.

Health Policy. 2002 Jan;59(1):65-94. Review.

PMID:
11786175
13.
14.

Penny and pound wise: pharmacoeconomics from a governmental perspective.

van Oostenbruggen MF, Jansen RB, Mur K, Kooijman H.

Pharmacoeconomics. 2005;23(3):219-26. Review.

PMID:
15836004
15.

Accounting for noncompliance in pharmacoeconomic evaluations.

Hughes DA, Bagust A, Haycox A, Walley T.

Pharmacoeconomics. 2001;19(12):1185-97. Review.

PMID:
11772154
16.

Pharmacoeconomics: an emerging discipline.

Letizia C.

Qual Assur. 1995 Mar;4(1):68-74.

PMID:
8520866
17.

Medication non-adherence--exploring the conceptual mire.

Lehane E, McCarthy G.

Int J Nurs Pract. 2009 Feb;15(1):25-31. doi: 10.1111/j.1440-172X.2008.01722.x. Review.

PMID:
19187166
18.

Update on pharmacoeconomics in transplantation.

Cavanaugh TM, Martin JE.

Prog Transplant. 2007 Jun;17(2):103-19; quiz 120. Review.

PMID:
17624133
19.

Drug utilisation studies as tools in health economics.

Sacristán JA, Soto J.

Pharmacoeconomics. 1994 Apr;5(4):299-312. Review.

PMID:
10147239
20.

Using economic evaluations to make formulary coverage decisions. So much for guidelines.

Anis AH, Gagnon Y.

Pharmacoeconomics. 2000 Jul;18(1):55-62.

PMID:
11010604
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk